Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Phase III, Controlled, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Capecitabine Therapy With Concurrent and Sequential Chemoimmunotherapy Using a Telomerase Vaccine in Locally Advanced and Metastatic Pancreatic Cancer [TELOVAC]

NCT00425360 is registered in ClinicalTrials.gov with Royal Liverpool University Hospital as lead sponsor.

NCT NCT00425360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00425360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Phase III, Controlled, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Capecitabine Therapy With Concurrent and Sequential Chemoimmunotherapy Using a Telomerase Vaccine in Locally Advanced and Metastatic Pancreatic Cancer [TELOVAC]
Lead sponsor
Royal Liverpool University Hospital
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2006
Completion date
March 31, 2013
Enrollment
1,110 (estimated)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer